CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | omega-6 fatty acid |
|
Accession: | CHEBI:36009
|
browse the term
|
Definition: | A family of polyunsaturated fatty acids that have in common a final carbon-carbon double bond in the n-6 position, i.e., the sixth bond from the methyl end of the fatty acid. |
Synonyms: | related_synonym: | omega-6 fatty acids |
| alt_id: | MESH:D043371 |
| xref_mesh: | MESH:D043371 |
| xref: | PMID:19035453; PMID:19136835 |
|
|
|
G |
Alg3 |
ALG3, alpha-1,3- mannosyltransferase |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of ALG3 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr11:83,985,484...83,991,706
Ensembl chr11:83,986,230...83,991,706
|
|
G |
Atp8a1 |
ATPase phospholipid transporting 8A1 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of ATP8A1 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr14:41,972,398...42,210,555
Ensembl chr14:42,015,347...42,206,311
|
|
G |
Ccnd1 |
cyclin D1 |
affects response to substance |
ISO |
CCND1 gene SNP affects the susceptibility to Fatty Acids, Omega-6 |
CTD |
PMID:15845652 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd84 |
CD84 molecule |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of CD84 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr13:90,241,369...90,283,625
Ensembl chr13:90,244,681...90,277,865
|
|
G |
Cpb2 |
carboxypeptidase B2 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of CPB2 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr15:57,290,849...57,339,762
Ensembl chr15:57,290,849...57,339,760
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of DGKE mRNA |
CTD |
PMID:16823509 |
|
NCBI chr10:76,375,981...76,408,224
Ensembl chr10:76,386,471...76,407,989
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of DUSP2 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr 3:119,776,925...119,779,110
Ensembl chr 3:119,776,925...119,779,099
|
|
G |
Ebi3 |
Epstein-Barr virus induced 3 |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of EBI3 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr 9:11,110,874...11,114,843
Ensembl chr 9:11,110,874...11,114,843
|
|
G |
Gars |
glycyl-tRNA synthetase |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of GARS1 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044
|
|
G |
Gjc1 |
gap junction protein, gamma 1 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of GJC1 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr10:90,781,408...90,912,440
Ensembl chr10:90,781,402...90,912,287
|
|
G |
Hs3st1 |
heparan sulfate-glucosamine 3-sulfotransferase 1 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of HS3ST1 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr14:75,880,410...75,881,346
Ensembl chr14:75,852,060...75,882,693
|
|
G |
Il1rap |
interleukin 1 receptor accessory protein |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of IL1RAP mRNA |
CTD |
PMID:16823509 |
|
NCBI chr11:77,456,648...77,593,208
Ensembl chr11:77,463,954...77,593,207
|
|
G |
Itgb4 |
integrin subunit beta 4 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of ITGB4 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr10:104,524,000...104,560,180
Ensembl chr10:104,523,996...104,561,078
|
|
G |
Kif4a |
kinesin family member 4A |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of KIF4A mRNA |
CTD |
PMID:16823509 |
|
NCBI chr X:70,461,700...70,561,084
Ensembl chr X:70,461,718...70,561,189
|
|
G |
Msln |
mesothelin |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of MSLN mRNA |
CTD |
PMID:16823509 |
|
NCBI chr10:15,119,700...15,129,129
Ensembl chr10:15,119,663...15,125,408
|
|
G |
Nudcd3 |
NudC domain containing 3 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of NUDCD3 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr14:86,326,413...86,333,397
Ensembl chr14:86,326,421...86,333,424
|
|
G |
Pcdh1 |
protocadherin 1 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of PCDH1 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr18:31,330,081...31,343,147
Ensembl chr18:31,328,919...31,343,797
|
|
G |
Phkg1 |
phosphorylase kinase catalytic subunit gamma 1 |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of PHKG1 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr12:30,450,431...30,464,314
Ensembl chr12:30,450,316...30,464,352
|
|
G |
Psmd11 |
proteasome 26S subunit, non-ATPase 11 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of PSMD11 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr10:67,810,655...67,857,562
Ensembl chr10:67,810,655...67,857,223
|
|
G |
Puf60 |
poly-U binding splicing factor 60 |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of PUF60 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr 7:117,129,237...117,140,234
Ensembl chr 7:117,129,237...117,140,214
|
|
G |
Ro60 |
Ro60, Y RNA binding protein |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of RO60 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr13:60,546,892...60,567,882
Ensembl chr13:60,546,912...60,567,882
|
|
G |
Sdc4 |
syndecan 4 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of SDC4 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr 3:160,872,503...160,891,190
Ensembl chr 3:160,872,503...160,891,190
|
|
G |
Slc1a6 |
solute carrier family 1 member 6 |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of SLC1A6 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr 7:13,730,101...13,758,170
Ensembl chr 7:13,730,253...13,751,271
|
|
G |
Slc26a4 |
solute carrier family 26 member 4 |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of SLC26A4 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr 6:50,809,103...50,848,443
Ensembl chr 6:50,808,923...50,846,965
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of SOAT1 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr13:74,035,258...74,077,759
Ensembl chr13:74,035,080...74,077,783
|
|
G |
Urb1 |
URB1 ribosome biogenesis homolog |
decreases expression |
ISO |
Fatty Acids, Omega-6 results in decreased expression of URB1 mRNA |
CTD |
PMID:16823509 |
|
NCBI chr11:30,916,740...30,977,423
Ensembl chr11:30,916,730...30,977,483
|
|
G |
Vti1b |
vesicle transport through interaction with t-SNAREs 1B |
increases expression |
ISO |
Fatty Acids, Omega-6 results in increased expression of VTI1B mRNA |
CTD |
PMID:16823509 |
|
NCBI chr 6:102,340,261...102,353,612
Ensembl chr 6:102,339,857...102,353,403
|
|
|
G |
Crp |
C-reactive protein |
affects expression |
ISO |
docosapentaenoic acid affects the expression of CRP protein |
CTD |
PMID:22113248 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
multiple interactions |
EXP |
docosapentaenoic acid inhibits the reaction [Ethanol results in decreased expression of PLA2G6 protein] |
CTD |
PMID:25029343 |
|
NCBI chr 7:120,519,479...120,559,716
Ensembl chr 7:120,519,467...120,559,347
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
EXP |
docosapentaenoic acid results in decreased expression of PTGS2 protein docosapentaenoic acid inhibits the reaction [Dimethoate results in increased expression of PTGS2 protein] |
CTD |
PMID:22476691 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
docosapentaenoic acid binds to RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:7,961,413...7,980,708
Ensembl chr 6:7,961,413...7,980,708
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolein results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolein results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:243,366,181...243,407,608
Ensembl chr 2:243,366,181...243,407,608
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:86,345,946...86,560,694
Ensembl chr14:86,345,953...86,560,694
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions decreases expression |
ISO |
Clofibrate inhibits the reaction [trilinolein results in decreased expression of SCD1 mRNA] |
CTD |
PMID:8790349 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
increases metabolic processing |
ISO |
DAGLA protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr 1:226,297,013...226,353,712
Ensembl chr 1:226,297,016...226,353,611
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases metabolic processing |
ISO |
DAGLB protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr12:13,113,073...13,157,748
Ensembl chr12:13,113,237...13,157,666
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
increases phosphorylation |
ISO |
DGKE protein results in increased phosphorylation of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:17455907 |
|
NCBI chr10:76,375,981...76,408,224
Ensembl chr10:76,386,471...76,407,989
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
1-stearoyl-2-arachidonoylglycerol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:234,478,908...234,631,264
Ensembl chr 1:234,479,289...234,596,971
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Cat |
catalase |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAT protein |
CTD |
PMID:10946007 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAV1 mRNA |
CTD |
PMID:27257344 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein |
CTD |
PMID:22135674 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein |
CTD |
PMID:22135674 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARA protein |
CTD |
PMID:22135674 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARG protein |
CTD |
PMID:22135674 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity |
EXP |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased activity of ACE protein |
CTD |
PMID:27428043 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein] |
CTD |
PMID:27428043 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Agt |
angiotensinogen |
decreases expression multiple interactions increases cleavage |
EXP ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form [14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7) 14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form] |
CTD |
PMID:27428043 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of AKT1 protein |
CTD |
PMID:16286479 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases chemical synthesis |
ISO |
CYP2C8 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:12675279 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions increases abundance |
ISO |
[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:19896470 PMID:22680237 PMID:24472606 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein |
CTD |
PMID:16286479 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19464254 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19464254 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:16286479 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases secretion multiple interactions |
ISO |
TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:28694203 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:146,630,298...146,690,375
Ensembl chr 3:146,630,299...146,690,375
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:18,647,903...18,695,133
Ensembl chr15:18,647,844...18,695,133
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate |
CTD |
PMID:29813086 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCR1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:132,996,646...133,002,201
Ensembl chr 8:132,996,649...133,002,201
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CD36 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:30102254 PMID:31024316 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:11,490,852...11,499,287
Ensembl chr 7:11,490,852...11,499,282
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance multiple interactions |
ISO |
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fmr1 |
FMRP translational regulator 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:154,684,924...154,722,369
Ensembl chr X:154,684,935...154,722,314
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:30301768 |
|
NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:132,702,443...132,726,848
Ensembl chr 6:132,702,448...132,727,046
|
|
|
G |
Clock |
clock circadian regulator |
affects abundance |
ISO |
CLOCK protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:22440902 |
|
NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions increases chemical synthesis |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]] CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:11124159 PMID:12388396 |
|
NCBI chr 5:134,492,734...134,507,158
Ensembl chr 5:134,492,756...134,507,154
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
increases expression |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of CYP4A2 mRNA |
CTD |
PMID:22442195 |
|
NCBI chr 5:134,196,910...134,207,888
Ensembl chr 5:134,196,912...134,207,863
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
multiple interactions increases localization |
ISO EXP |
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein] |
CTD |
PMID:16055480 |
|
NCBI chr15:34,493,163...34,502,238
Ensembl chr15:34,493,138...34,504,326
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases abundance |
EXP |
N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid] POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:18067589 PMID:19458537 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,256,628...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:22,597,103...22,619,968
|
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases abundance |
ISO |
EPHX2 gene mutant form results in increased abundance of 5,6-epoxy-8,11,14-eicosatrienoic acid |
CTD |
PMID:19896470 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects hydrolysis |
ISO |
EPHX1 protein affects the hydrolysis of 8,9-epoxyeicosatrienoic acid |
CTD |
PMID:28975360 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases abundance |
ISO |
EPHX2 gene mutant form results in increased abundance of 8,9-epoxyeicosatrienoic acid |
CTD |
PMID:19896470 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [AGT protein results in increased abundance of Epoprostenol] |
CTD |
PMID:14613874 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:18938131 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] |
CTD |
PMID:19014389 |
|
NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Ins2 |
insulin 2 |
increases secretion multiple interactions |
ISO |
arachidonyltrifluoromethane results in increased secretion of INS protein arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:17192482 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15231676 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Oxaliplatin] |
CTD |
PMID:25940438 |
|
NCBI chr 2:193,863,185...193,868,646
Ensembl chr 2:193,866,951...193,868,502
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]] |
CTD |
PMID:19063610 PMID:19162293 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
adrenic acid binds to and results in increased activity of RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of adrenic acid |
CTD |
PMID:30258081 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of anandamide |
CTD |
PMID:30102254 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein |
CTD |
PMID:30610963 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance decreases metabolic processing decreases abundance |
EXP ISO |
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide |
CTD |
PMID:22233683 PMID:26976670 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions decreases activity |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:26513129 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein |
CTD |
PMID:17360047 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
anandamide results in decreased expression of CGA mRNA |
CTD |
PMID:30610963 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects activity increases response to substance decreases expression affects binding increases activity multiple interactions |
ISO EXP |
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] |
CTD |
PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 PMID:15453094 PMID:17557913 PMID:19147270 PMID:29730318 PMID:31024316 PMID:31199905 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects activity affects binding multiple interactions |
ISO EXP |
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide] |
CTD |
PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:30610963 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crh |
corticotropin releasing hormone |
decreases abundance |
ISO |
CRH protein results in decreased abundance of anandamide |
CTD |
PMID:26821211 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein] |
CTD |
PMID:21949157 PMID:26513129 PMID:29441458 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:26513129 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
decreases expression |
ISO |
anandamide results in decreased expression of ERVFRD-1 mRNA |
CTD |
PMID:30610963 |
|
NCBI chr12:25,161,130...25,168,182
Ensembl chr12:25,161,130...25,168,182
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] anandamide results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Faah |
fatty acid amide hydrolase |
increases degradation multiple interactions affects expression |
ISO EXP |
FAAH results in increased degradation of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide |
CTD |
PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 PMID:23761300 PMID:26642910 PMID:29787777 PMID:31121907 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Faahl |
fatty-acid amide hydrolase-like |
increases degradation affects expression multiple interactions |
ISO |
FAAH results in increased degradation of anandamide anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide |
CTD |
PMID:16131814 PMID:16886060 PMID:20702753 PMID:31121907 |
|
NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions affects abundance affects binding |
EXP ISO |
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 PMID:30232874 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein |
CTD |
PMID:9748483 PMID:15601931 PMID:19515121 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] |
CTD |
PMID:12813001 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
anandamide results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:15748152 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] |
CTD |
PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:30611738 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Lep |
leptin |
decreases abundance multiple interactions decreases activity decreases transport |
ISO |
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide |
CTD |
PMID:16154199 PMID:29967158 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
anandamide results in increased expression of MMP1 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
anandamide results in increased expression of MMP3 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:11891798 PMID:15748152 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
anandamide results in increased cleavage of PARP1 protein |
CTD |
PMID:29441458 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
anandamide binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing |
EXP ISO |
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide] |
CTD |
PMID:16330497 PMID:17245358 PMID:20702753 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein |
CTD |
PMID:27151562 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance |
EXP ISO |
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF] |
CTD |
PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases response to substance increases activity affects response to substance affects binding |
ISO EXP |
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein |
CTD |
PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 PMID:15615864 PMID:17038422 PMID:17913835 PMID:18550765 PMID:21949157 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
anandamide results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:15313899 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases degradation |
ISO |
Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Arachidonic Acid results in increased degradation of ABCA1 protein |
CTD |
PMID:16118212 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [GW 4064 results in increased expression of ABCB11 mRNA] |
CTD |
PMID:15307955 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ABCD3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:225,335,708...225,389,120
Ensembl chr 2:225,335,718...225,389,120
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ABCG1 mRNA |
CTD |
PMID:16730733 |
|
NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
|
|
G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ADARB1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:11,972,352...12,101,022
Ensembl chr20:11,972,381...12,101,047
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
Eicosapentaenoic Acid inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]; Quinacrine inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid] |
CTD |
PMID:16257180 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]] |
CTD |
PMID:19162293 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Arachidonic Acid results in increased phosphorylation of AKT1 protein aristolochic acid I inhibits the reaction [Arachidonic Acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19344371 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
affects response to substance increases metabolic processing |
ISO |
ALOX12 protein affects the susceptibility to Arachidonic Acid ALOX12 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:17027136 PMID:19373248 |
|
NCBI chr10:56,851,734...56,864,049
Ensembl chr10:56,851,734...56,864,005
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
multiple interactions |
ISO |
[TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid |
CTD |
PMID:30258081 |
|
NCBI chr10:55,744,646...55,756,524
Ensembl chr10:55,744,588...55,756,566
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
affects metabolic processing multiple interactions increases metabolic processing |
ISO |
ALOX15 protein affects the metabolism of Arachidonic Acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which affects the susceptibility to Acetylcholine; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,12,15-trihydroxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,14,15-trihydroxyeicosa-5,8,12-trienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-11,12-epoxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of Dinoprostone; ALOX15 protein results in increased metabolism of and affects the susceptibility to Arachidonic Acid ALOX15 protein results in increased metabolism of Arachidonic Acid [IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA |
CTD |
PMID:8305483 PMID:11861792 PMID:21193584 PMID:23872364 |
|
NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases metabolic processing |
ISO |
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [Sorbitol co-treated with Calcimycin co-treated with Arachidonic Acid] affects the localization of ALOX5 protein; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which affects the abundance of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which results in decreased susceptibility to Arachidonic Acid; Arachidonic Acid inhibits the reaction [L 708714 binds to ALOX5 protein]; CJ 13610 inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]; zileuton inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid] |
CTD |
PMID:7577949 PMID:7592874 PMID:9495842 PMID:10779545 PMID:11698504 PMID:18295198 PMID:30258081 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions decreases expression |
ISO |
Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Arachidonic Acid results in decreased expression of APOA1 mRNA |
CTD |
PMID:7983038 PMID:16118212 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Apoc1 |
apolipoprotein C1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of APOC1 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 1:80,606,638...80,609,921
Ensembl chr 1:80,606,638...80,609,921
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions decreases response to substance |
ISO |
APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid] |
CTD |
PMID:20530721 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
App |
amyloid beta precursor protein |
increases secretion multiple interactions |
ISO |
APP protein modified form results in increased secretion of Arachidonic Acid [1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of AQP3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Arachidonic Acid results in increased expression of ARHGDIA mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [Quercetin results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:20551291 |
|
NCBI chr 7:141,882,261...141,924,790
Ensembl chr 7:141,882,251...141,924,788
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases phosphorylation |
ISO |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of ATF2 protein] |
CTD |
PMID:19720122 |
|
NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of ATF3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Avp |
arginine vasopressin |
increases abundance |
EXP |
AVP protein results in increased abundance of Arachidonic Acid |
CTD |
PMID:11356622 |
|
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein] |
CTD |
PMID:30626086 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Barx1 |
BARX homeobox 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of BARX1 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr17:14,824,721...14,828,196
Ensembl chr17:14,824,734...14,828,329
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects localization |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid affects the localization of BAX protein] |
CTD |
PMID:19540902 PMID:19720122 PMID:30626086 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Arachidonic Acid results in decreased expression of BCL2 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein] |
CTD |
PMID:19540902 PMID:19620254 PMID:19720122 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19540902 PMID:19620254 PMID:19720122 PMID:27916511 PMID:30626086 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of BDNF mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage multiple interactions |
ISO |
Arachidonic Acid results in increased cleavage of BID protein FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein] |
CTD |
PMID:19720122 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases degradation |
ISO |
Arachidonic Acid results in increased activity of CASP3 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased degradation of CASP3 protein alternative form]; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein] |
CTD |
PMID:16704987 PMID:19540902 PMID:19620254 PMID:19720122 PMID:23266427 PMID:27916511 PMID:30626086 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein] |
CTD |
PMID:19720122 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Arachidonic Acid results in increased activity of CASP9 protein |
CTD |
PMID:19540902 PMID:19720122 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
increases activity |
EXP |
Arachidonic Acid results in increased activity of CAT protein |
CTD |
PMID:7548195 PMID:16982041 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA] |
CTD |
PMID:15684433 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity multiple interactions |
ISO |
Arachidonic Acid results in decreased activity of CES1 protein [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:19761868 PMID:21049984 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
CNR2 protein affects the reaction [Arachidonic Acid results in increased expression of CXCL8 protein] |
CTD |
PMID:15115777 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of COL18A1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
Arachidonic Acid results in increased expression of CPT1A mRNA |
CTD |
PMID:15307955 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
EXP |
Arachidonic Acid results in increased phosphorylation of CREB1 protein Ketoconazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:17680988 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Csk |
C-terminal Src kinase |
increases activity affects localization |
ISO |
Arachidonic Acid results in increased activity of CSK protein Arachidonic Acid affects the localization of CSK protein |
CTD |
PMID:18388244 |
|
NCBI chr 8:62,405,714...62,424,707
Ensembl chr 8:62,405,715...62,424,303
|
|
G |
Ctdspl |
CTD small phosphatase like |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of CTDSPL mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 8:127,065,292...127,726,248
Ensembl chr 8:127,702,534...127,726,127
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Arachidonic Acid affects the localization of CYCS protein |
CTD |
PMID:19720122 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
EXP |
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid] |
CTD |
PMID:16581302 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects metabolic processing multiple interactions |
ISO |
CYP1A1 protein affects the metabolism of Arachidonic Acid Arachidonic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:15258110 PMID:19063610 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing decreases activity |
ISO |
CYP1A2 protein results in increased metabolism of Arachidonic Acid Arachidonic Acid results in decreased activity of CYP1A2 protein |
CTD |
PMID:12675279 PMID:16978661 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects metabolic processing |
ISO |
CYP1B1 protein affects the metabolism of Arachidonic Acid |
CTD |
PMID:15258110 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of CYP24A1 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases metabolic processing |
ISO |
CYP2B6 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:12675279 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity increases metabolic processing multiple interactions |
ISO |
Arachidonic Acid results in decreased activity of CYP2C19 protein CYP2C19 protein results in increased metabolism of Arachidonic Acid CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP] |
CTD |
PMID:12675279 PMID:16978661 PMID:18004210 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases metabolic processing |
ISO |
CYP2C8 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:12675279 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:12675279 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions affects hydroxylation increases response to substance decreases activity |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; Cadmium Chloride affects the reaction [CYP2E1 protein results in increased susceptibility to Arachidonic Acid]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; CYP2E1 results in increased susceptibility to [Arachidonic Acid co-treated with Zinc Sulfate]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Arachidonic Acid] CYP2E1 protein affects the hydroxylation of Arachidonic Acid Arachidonic Acid results in decreased activity of CYP2E1 protein |
CTD |
PMID:12086689 PMID:12566070 PMID:15205388 PMID:16978661 PMID:17034788 PMID:21352821 PMID:22486562 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [CYP2J2 protein results in decreased methylation of Astemizole] |
CTD |
PMID:12386130 |
|
NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions increases metabolic processing decreases activity |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in decreased activity of CYP3A4 protein |
CTD |
PMID:12675279 PMID:16978661 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
multiple interactions increases hydroxylation |
ISO |
rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid] |
CTD |
PMID:30259074 |
|
NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
|
|
G |
Dct |
dopachrome tautomerase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of DCT mRNA |
CTD |
PMID:16623957 |
|
NCBI chr15:103,208,174...103,245,033
Ensembl chr15:103,208,258...103,244,494
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of DDIT4 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddx24 |
DEAD-box helicase 24 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of DDX24 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:127,302,201...127,319,382
Ensembl chr 6:127,302,201...127,319,362
|
|
G |
Des |
desmin |
increases expression |
EXP |
Arachidonic Acid results in increased expression of DES mRNA |
CTD |
PMID:19089455 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of EBP mRNA |
CTD |
PMID:16704987 |
|
NCBI chr X:15,049,394...15,055,782
Ensembl chr X:15,049,462...15,055,781
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein] |
CTD |
PMID:15525798 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of EGR1 mRNA |
CTD |
PMID:8764118 PMID:16704987 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Eif4ebp3 |
eukaryotic translation initiation factor 4E binding protein 3 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Quercetin results in decreased phosphorylation of EIF4EBP3 protein] |
CTD |
PMID:20551291 |
|
NCBI chr18:29,490,981...29,492,727
Ensembl chr18:29,386,809...29,492,718
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases metabolic processing |
ISO |
EPHX2 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:26165641 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Erg28 |
ergosterol biosynthesis 28 homolog |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ERG28 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:109,683,252...109,692,218
Ensembl chr 6:109,683,253...109,692,218
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Arachidonic Acid results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Faah |
fatty acid amide hydrolase |
multiple interactions increases chemical synthesis |
EXP |
Nitroglycerin promotes the reaction [FAAH protein results in increased chemical synthesis of Arachidonic Acid] |
CTD |
PMID:19515121 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein] |
CTD |
PMID:19720122 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions |
ISO |
[geraniol results in decreased activity of FADS1 protein] which results in decreased chemical synthesis of Arachidonic Acid |
CTD |
PMID:16462894 |
|
NCBI chr 1:226,234,034...226,249,118
Ensembl chr 1:226,234,074...226,249,138
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of FADS2 mRNA |
CTD |
PMID:21457203 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein] Arachidonic Acid results in increased expression of FAS mRNA; Arachidonic Acid results in increased expression of FAS protein |
CTD |
PMID:19720122 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein] Arachidonic Acid results in increased expression of FASLG mRNA; Arachidonic Acid results in increased expression of FASLG protein |
CTD |
PMID:19720122 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of FASN mRNA |
CTD |
PMID:19159447 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of FGFR3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases phosphorylation |
ISO |
[Arachidonic Acid co-treated with Quercetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of FOS protein; Arachidonic Acid inhibits the reaction [Quercetin results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA] Arachidonic Acid results in decreased phosphorylation of FOS protein |
CTD |
PMID:8764118 PMID:10864209 PMID:15878913 PMID:16704987 PMID:19720122 PMID:20551291 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Arachidonic Acid results in increased expression of FOSL1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Gap43 |
growth associated protein 43 |
increases phosphorylation |
ISO |
Arachidonic Acid results in increased phosphorylation of GAP43 protein |
CTD |
PMID:9852580 |
|
NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression increases activity |
ISO |
Arachidonic Acid results in increased expression of GCLC mRNA Arachidonic Acid results in increased activity of GCLC protein |
CTD |
PMID:16704987 PMID:17092368 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Arachidonic Acid results in increased expression of GCLM mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Glrx |
glutaredoxin |
affects response to substance |
ISO |
GLRX protein affects the susceptibility to Arachidonic Acid |
CTD |
PMID:19373248 |
|
NCBI chr 2:2,606,032...2,615,944
Ensembl chr 2:2,605,996...2,615,944
|
|
G |
Gnpda1 |
glucosamine-6-phosphate deaminase 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of GNPDA1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr18:31,479,117...31,489,154
Ensembl chr18:31,479,117...31,487,671
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein] |
CTD |
PMID:27916511 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Iodoacetates results in decreased activity of GPX1 protein] which affects the metabolism of Arachidonic Acid |
CTD |
PMID:11115402 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
[Iodoacetates results in decreased activity of GPX4 protein] which affects the metabolism of Arachidonic Acid; Arachidonic Acid promotes the reaction [Sodium Selenite results in increased expression of and results in increased activity of GPX4 protein] |
CTD |
PMID:11115402 PMID:14642406 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[SB 216763 results in decreased activity of GSK3B protein] results in decreased susceptibility to [Arachidonic Acid co-treated with Iron] |
CTD |
PMID:19620254 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of HMGCR mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression decreases response to substance |
ISO EXP |
Arachidonic Acid results in increased expression of HMOX1 mRNA HMOX1 protein results in decreased susceptibility to Arachidonic Acid |
CTD |
PMID:15036350 PMID:16704987 PMID:17092368 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hs2st1 |
heparan sulfate 2-O-sulfotransferase 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of HS2ST1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:250,467,428...250,600,517
Ensembl chr 2:250,467,429...250,600,517
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hspb11 |
heat shock protein family B (small), member 11 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of HSPB11 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:126,856,128...126,882,913
Ensembl chr 5:126,856,705...126,882,909
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11356925 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Id3 |
inhibitor of DNA binding 3, HLH protein |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ID3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:154,489,603...154,491,172
Ensembl chr 5:154,489,590...154,491,223
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of IDI1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of IGFBP7 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr14:33,010,300...33,070,193
Ensembl chr14:33,010,300...33,070,190
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA] |
CTD |
PMID:15684433 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[IL1A protein co-treated with Arachidonic Acid] results in increased abundance of Dinoprostone |
CTD |
PMID:11351503 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:11112151 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA |
CTD |
PMID:11861792 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
Arachidonic Acid results in increased secretion of IL6 protein |
CTD |
PMID:20436887 PMID:21457203 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ilvbl |
ilvB acetolactate synthase like |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ILVBL mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:14,044,586...14,054,639
Ensembl chr 7:14,044,586...14,054,639
|
|
G |
Ins2 |
insulin 2 |
increases secretion multiple interactions |
ISO |
Arachidonic Acid results in increased secretion of INS protein Arachidonic Acid promotes the reaction [Glucose results in increased secretion of INS protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]; phenidone promotes the reaction [Arachidonic Acid results in increased secretion of INS protein] |
CTD |
PMID:17192482 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ISL1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:48,488,911...48,501,217
Ensembl chr 2:48,487,736...48,501,436
|
|
G |
Itga2b |
integrin subunit alpha 2b |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of ITGA2B protein Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]] |
CTD |
PMID:18413191 |
|
NCBI chr10:90,397,960...90,416,550
Ensembl chr10:90,398,132...90,415,070
|
|
G |
Itga6 |
integrin subunit alpha 6 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of ITGA6 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:58,442,904...58,515,124
Ensembl chr 3:58,443,101...58,515,124
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions increases expression |
ISO |
Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein] |
CTD |
PMID:18413191 PMID:23249183 |
|
NCBI chr10:92,667,869...92,783,413
Ensembl chr10:92,667,869...92,783,410
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of JUN mRNA Arachidonic Acid results in increased expression of and results in increased phosphorylation of JUN protein; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein] |
CTD |
PMID:8764118 PMID:16704987 PMID:19720122 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA] Arachidonic Acid results in increased expression of JUNB mRNA |
CTD |
PMID:8764118 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Kcnk10 |
potassium two pore domain channel subfamily K member 10 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr 6:122,417,079...122,549,532
Ensembl chr 6:122,419,046...122,545,899
|
|
G |
Kcnk2 |
potassium two pore domain channel subfamily K member 2 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [KCNK2 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr13:107,690,111...107,886,476
Ensembl chr13:107,690,087...107,886,476
|
|
G |
Kcnk4 |
potassium two pore domain channel subfamily K member 4 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [KCNK4 protein results in increased transport of Potassium] |
CTD |
PMID:10767409 PMID:16075240 |
|
NCBI chr 1:222,182,997...222,192,139
Ensembl chr 1:222,183,276...222,189,604
|
|
G |
Klf5 |
Kruppel-like factor 5 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of KLF5 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
|
|
G |
Klf6 |
Kruppel-like factor 6 |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of KLF6 mRNA; Arachidonic Acid results in increased expression of KLF6 mRNA alternative form; Arachidonic Acid results in increased expression of KLF6 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [Arachidonic Acid co-treated with Hydrogen Peroxide] results in increased expression of KLF6 protein; [Arachidonic Acid co-treated with SB 203580] results in decreased expression of KLF6 mRNA; [Arachidonic Acid co-treated with Vitamin K 3] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid inhibits the reaction [pyrazolanthrone results in decreased expression of KLF6 mRNA]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]] |
CTD |
PMID:22486562 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [GW 4064 results in increased expression of KNG1 mRNA] |
CTD |
PMID:15307955 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of LAMP2 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr X:124,722,628...124,766,079
Ensembl chr X:124,722,628...124,766,044
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions decreases response to substance |
ISO |
Aspirin inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid Aspirin inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid] |
CTD |
PMID:20530721 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance multiple interactions |
ISO |
LIPC gene mutant form results in decreased abundance of Arachidonic Acid [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance multiple interactions |
ISO |
LIPG gene mutant form results in decreased abundance of Arachidonic Acid [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
G |
Lrat |
lecithin retinol acyltransferase |
increases expression |
EXP |
Arachidonic Acid results in increased expression of LRAT mRNA |
CTD |
PMID:12576510 |
|
NCBI chr 2:181,896,304...181,905,366
Ensembl chr 2:181,896,305...181,905,300
|
|
G |
Lss |
lanosterol synthase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of LSS mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:12,844,522...12,870,474
Ensembl chr20:12,842,884...12,870,497
|
|
G |
Ltb4r |
leukotriene B4 receptor |
affects response to substance |
ISO |
LTB4R1 protein affects the susceptibility to Arachidonic Acid |
CTD |
PMID:10934231 |
|
NCBI chr15:34,449,299...34,453,352
Ensembl chr15:34,452,116...34,453,171
|
|
G |
Luc7l3 |
LUC7-like 3 pre-mRNA splicing factor |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of LUC7L3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:81,991,147...82,027,119
Ensembl chr10:81,991,147...82,027,119
|
|
G |
Maff |
MAF bZIP transcription factor F |
increases expression |
ISO |
Arachidonic Acid results in increased expression of MAFF mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein] |
CTD |
PMID:19720122 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation affects abundance multiple interactions |
ISO EXP |
Arachidonic Acid results in increased phosphorylation of MAPK1 protein MAPK1 protein affects the abundance of Arachidonic Acid [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16216387 PMID:19464254 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO EXP |
MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein] MAPK14 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid] |
CTD |
PMID:16120751 PMID:19540902 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions affects abundance increases phosphorylation |
ISO EXP |
[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein] MAPK3 protein affects the abundance of Arachidonic Acid |
CTD |
PMID:16216387 PMID:19464254 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19540902 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapt |
microtubule-associated protein tau |
increases phosphorylation multiple interactions |
ISO |
Arachidonic Acid results in increased phosphorylation of MAPT protein Ro 31-8220 inhibits the reaction [Arachidonic Acid results in increased phosphorylation of MAPT protein] |
CTD |
PMID:12605413 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases secretion multiple interactions increases expression |
ISO |
Arachidonic Acid results in increased secretion of MMP13 protein Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP13 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP13 protein] |
CTD |
PMID:16185265 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression increases secretion |
ISO |
Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP2 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP2 protein] |
CTD |
PMID:16185265 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions increases secretion |
ISO |
Arachidonic Acid results in increased expression of MMP9 mRNA Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP9 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP9 protein] |
CTD |
PMID:16185265 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
increases secretion multiple interactions increases expression |
ISO |
Arachidonic Acid results in increased secretion of MPO protein 5-((1,5-bis(4-methoxyphenyl)pyrazol-3-yl)dimethoxymethyl)-2-chlorobenzamide inhibits the reaction [Arachidonic Acid results in increased expression of MPO protein] |
CTD |
PMID:3111576 PMID:9831321 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA] |
CTD |
PMID:12566070 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[Quercetin co-treated with Arachidonic Acid] results in decreased phosphorylation of MTOR protein |
CTD |
PMID:20551291 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions increases localization |
ISO |
Adiponectin inhibits the reaction [Arachidonic Acid results in increased localization of NCF1 protein]; Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein] |
CTD |
PMID:12101222 PMID:20832062 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF2 protein] |
CTD |
PMID:12101222 |
|
NCBI chr13:70,226,441...70,259,019
Ensembl chr13:70,226,647...70,257,576
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
Arachidonic Acid results in increased cleavage of and results in increased secretion of NOX1 protein; Cholesterol, LDL affects the reaction [Adiponectin inhibits the reaction [Arachidonic Acid results in increased cleavage of NOX1 protein]] |
CTD |
PMID:20832062 |
|
NCBI chr X:104,909,328...104,932,508
Ensembl chr X:104,909,326...104,932,508
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects binding multiple interactions |
ISO |
Arachidonic Acid binds to NR1H4 protein Arachidonic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] |
CTD |
PMID:15307955 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of NR2F1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of NR4A2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:43,111,258...43,128,391
Ensembl chr 3:43,111,240...43,119,159
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions decreases chemical synthesis |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in decreased abundance of Arachidonic Acid analog NR5A2 gene mutant form results in decreased chemical synthesis of Arachidonic Acid |
CTD |
PMID:29515023 |
|
NCBI chr13:53,750,470...53,870,288
Ensembl chr13:53,750,473...53,870,428
|
|
G |
Nrtn |
neurturin |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of NRTN mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 9:10,299,881...10,306,599
Ensembl chr 9:10,305,470...10,306,597
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased cleavage of PARP1 protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form] |
CTD |
PMID:10403056 PMID:19540902 PMID:21132278 PMID:30626086 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pde4dip |
phosphodiesterase 4D interacting protein |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of PDE4DIP mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:199,867,965...200,066,034
Ensembl chr 2:199,867,972...200,003,443
|
|
G |
Pdss2 |
decaprenyl diphosphate synthase subunit 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of PDSS2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:47,966,513...48,192,747
Ensembl chr20:47,966,583...48,192,743
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PHLDA1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
multiple interactions increases expression |
ISO EXP |
AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA] PLA2G4A protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid] Arachidonic Acid results in increased expression of PLA2G4A mRNA; Arachidonic Acid results in increased expression of PLA2G4A protein |
CTD |
PMID:15878913 PMID:16120751 PMID:19162293 |
|
NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions |
ISO |
PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Arachidonic Acid] |
CTD |
PMID:9495842 |
|
NCBI chr 5:157,247,601...157,268,968
Ensembl chr 5:157,247,781...157,268,903
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
multiple interactions |
EXP |
PLA2G6 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid] |
CTD |
PMID:16120751 |
|
NCBI chr 7:120,519,479...120,559,716
Ensembl chr 7:120,519,467...120,559,347
|
|
G |
Plaa |
phospholipase A2, activating protein |
multiple interactions |
ISO |
PLAA protein promotes the reaction [Lipopolysaccharides results in increased abundance of Arachidonic Acid] |
CTD |
PMID:11094054 |
|
NCBI chr 5:113,548,913...113,578,928
Ensembl chr 5:113,548,913...113,578,928
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO EXP |
Arachidonic Acid results in increased expression of PLIN2 mRNA Arachidonic Acid results in increased expression of PLIN2 mRNA; Arachidonic Acid results in increased expression of PLIN2 protein |
CTD |
PMID:16489205 |
|
NCBI chr 5:104,984,413...105,010,863
Ensembl chr 5:104,984,414...105,010,857
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PMAIP1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions decreases activity |
ISO |
Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] Arachidonic Acid results in decreased activity of PON1 protein |
CTD |
PMID:15375178 |
|
NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of PPARA mRNA; Arachidonic Acid results in increased expression of PPARA protein Arachidonic Acid binds to and results in increased activity of PPARA protein |
CTD |
PMID:10403814 PMID:11172467 PMID:15491415 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PPARD mRNA |
CTD |
PMID:11172467 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression increases expression multiple interactions |
ISO EXP |
Arachidonic Acid results in decreased expression of PPARG mRNA; Arachidonic Acid results in decreased expression of PPARG protein Arachidonic Acid results in increased expression of PPARG protein Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA] |
CTD |
PMID:11172467 PMID:12604186 PMID:19063610 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of PPP1CA mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 1:219,439,953...219,443,570
Ensembl chr 1:219,439,953...219,443,570
|
|
G |
Prpf4 |
pre-mRNA processing factor 4 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of PRPF4 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:78,267,248...78,281,172
Ensembl chr 5:78,267,248...78,281,172
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PSAT1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:233,124,089...233,145,941
Ensembl chr 1:233,124,092...233,145,941
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions |
EXP |
[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of PTAFR mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of PTAFR mRNA] |
CTD |
PMID:17515866 |
|
NCBI chr 5:150,746,284...150,775,675
Ensembl chr 5:150,754,021...150,775,672
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases activity increases response to substance increases metabolic processing multiple interactions |
ISO |
Arachidonic Acid results in increased activity of PTGS1 protein PTGS1 results in increased susceptibility to Arachidonic Acid PTGS1 protein alternative form results in increased metabolism of Arachidonic Acid; PTGS1 protein results in increased metabolism of Arachidonic Acid [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; DuP 697 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; Resveratrol inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; SC 560 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; valerylsalicylate inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein] |
CTD |
PMID:15863457 PMID:16141368 PMID:19751497 PMID:20933508 PMID:21163909 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing increases response to substance increases activity |
ISO EXP |
[[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine; [lenabasum results in increased expression of PTGS2 mRNA] which results in increased secretion of Arachidonic Acid; [PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA; Arachidonic Acid inhibits the reaction [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone binds to and results in decreased activity of PTGS2 protein]; Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS2 protein]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; nimesulide inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in increased expression of PTGS2 protein PTGS2 results in increased susceptibility to Arachidonic Acid 12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 2-methoxybenzoic acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid; [nimesulide results in decreased expression of PTGS2] which results in increased abundance of Arachidonic Acid; [PTGS2 protein results in increased abundance of prostaglandin G2] inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; Arachidonic Acid affects the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Benzoic Acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; Eugenol inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid]; Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in increased expression of PTGS2 mRNA; Arachidonic Acid results in increased expression of PTGS2 protein |
CTD |
PMID:9013627 PMID:9146894 PMID:11112151 PMID:12538810 PMID:12757841 PMID:12821125 PMID:15684433 PMID:15863457 PMID:15878913 PMID:17092368 PMID:17624748 PMID:18297109 PMID:18388244 PMID:18840450 PMID:19063610 PMID:21163909 PMID:22476691 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PTP4A1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 9:37,223,363...37,254,222
Ensembl chr 9:37,223,729...37,231,291
|
|
G |
Rapgef2 |
Rap guanine nucleotide exchange factor 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of RAPGEF2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:177,836,191...178,057,378
Ensembl chr 2:177,836,202...178,057,157
|
|
G |
Retn |
resistin |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of RETN mRNA |
CTD |
PMID:15949695 |
|
NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Quercetin results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:20551291 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
Arachidonic Acid binds to RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SCD mRNA |
CTD |
PMID:21457203 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Selp |
selectin P |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of SELP protein Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein] |
CTD |
PMID:17543677 PMID:18413191 PMID:23249183 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SERPINB2 mRNA |
CTD |
PMID:18388244 |
|
NCBI chr13:27,449,907...27,463,015
Ensembl chr13:27,449,934...27,463,010
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SKP2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:58,506,146...58,534,211
Ensembl chr 2:58,506,151...58,534,211
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SLC4A2 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 4:7,264,677...7,282,355
Ensembl chr 4:7,264,683...7,281,223
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SLC7A11 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SNAI2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases activity increases activity multiple interactions |
EXP |
Arachidonic Acid results in decreased activity of SOD1 protein Arachidonic Acid results in increased activity of SOD1 protein 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein] |
CTD |
PMID:16982041 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases activity increases expression |
ISO EXP |
[Arachidonic Acid results in increased abundance of Reactive Oxygen Species] which results in increased expression of SOD2; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Arachidonic Acid results in increased expression of and results in increased activity of SOD2 protein; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Dactinomycin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Phenols inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein] Arachidonic Acid results in increased activity of SOD2 protein 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein] |
CTD |
PMID:12031898 PMID:16982041 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SOX9 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SPARC mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:40,742,390...40,764,232
Ensembl chr10:40,742,400...40,764,185
|
|
G |
Spast |
spastin |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SPAST mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:22,230,067...22,282,166
Ensembl chr 6:22,230,928...22,281,886
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SQSTM1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srgap2 |
SLIT-ROBO Rho GTPase activating protein 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SRGAP2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr13:48,065,280...48,286,888
Ensembl chr13:48,068,158...48,286,720
|
|
G |
Ssr2 |
signal sequence receptor subunit 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SSR2 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 2:187,951,316...187,960,067
Ensembl chr 2:187,951,344...187,960,063
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
EXP |
Arachidonic Acid results in increased expression of STAR protein Arachidonic Acid inhibits the reaction [Dimethoate results in decreased expression of STAR protein] |
CTD |
PMID:22476691 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Stc2 |
stanniocalcin 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of STC2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:16,542,909...16,552,675
Ensembl chr10:16,542,882...16,553,295
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
STK11 protein affects the reaction [resveratrol results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]] |
CTD |
PMID:19620254 |
|
NCBI chr 7:12,440,751...12,457,513
Ensembl chr 7:12,440,751...12,457,513
|
|
G |
Tfeb |
transcription factor EB |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of TFEB mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 9:15,208,141...15,264,101
Ensembl chr 9:15,207,822...15,214,596
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression multiple interactions |
ISO |
Arachidonic Acid results in decreased expression of THRSP mRNA Flurbiprofen inhibits the reaction [Arachidonic Acid results in decreased expression of THRSP mRNA] |
CTD |
PMID:10357836 |
|
NCBI chr 1:162,381,251...162,385,575
Ensembl chr 1:162,381,253...162,385,575
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of TLR4 mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of TLR4 mRNA] |
CTD |
PMID:17515866 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance increases secretion |
ISO |
Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased secretion of Arachidonic Acid] TNF protein results in increased abundance of Arachidonic Acid Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]; TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]] |
CTD |
PMID:1515551 PMID:10588948 PMID:15684433 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
ISO |
Arachidonic Acid results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:12,995,904...12,997,930
Ensembl chr10:12,995,904...12,997,930
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]] |
CTD |
PMID:10588948 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Tns3 |
tensin 3 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of TNS3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr14:88,673,922...88,907,874
Ensembl chr14:88,673,881...88,886,198
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of TOP2A mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:86,901,467...86,930,947
Ensembl chr10:86,901,007...86,932,154
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid [TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid |
CTD |
PMID:30258081 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity multiple interactions |
ISO |
Arachidonic Acid results in increased activity of TRPA1 protein Ruthenium Red inhibits the reaction [Arachidonic Acid results in increased activity of TRPA1 protein] |
CTD |
PMID:15046718 |
|
NCBI chr 5:3,783,247...3,836,485
Ensembl chr 5:3,783,247...3,836,485
|
|
G |
Trpc4 |
transient receptor potential cation channel, subfamily C, member 4 |
multiple interactions |
ISO |
TRPC4 protein affects the reaction [Arachidonic Acid results in increased transport of Calcium] |
CTD |
PMID:11830588 |
|
NCBI chr 2:143,433,102...143,605,757
Ensembl chr 2:143,475,323...143,604,972
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
[Arachidonic Acid co-treated with Phorbol 12,13-Dibutyrate] results in increased activity of TRPV1 protein |
CTD |
PMID:17038422 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases activity |
ISO |
Arachidonic Acid results in increased activity of TRPV4 protein |
CTD |
PMID:20956320 |
|
NCBI chr12:47,698,915...47,737,902
Ensembl chr12:47,698,947...47,737,902
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,285,592...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,256,628...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr14:22,597,103...22,619,968
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
[PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein] Arachidonic Acid results in increased expression of VEGFA mRNA |
CTD |
PMID:12821125 PMID:18388244 PMID:19464254 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
increases expression |
ISO |
Arachidonic Acid results in increased expression of YWHAZ mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:75,573,553...75,598,295
Ensembl chr 7:75,574,967...75,597,276
|
|
G |
Zfp36 |
zinc finger protein 36 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of ZFP36 mRNA |
CTD |
PMID:8764118 |
|
NCBI chr 1:85,380,088...85,382,565
Ensembl chr 1:85,380,088...85,382,569
|
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions decreases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions affects abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate LIPG gene mutant form affects the abundance of cholesteryl linoleate |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of AKR1C4 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr17:69,441,253...69,460,334
Ensembl chr17:69,441,223...69,460,321
|
|
G |
Apoh |
apolipoprotein H |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of APOH mRNA |
CTD |
PMID:20664735 |
|
NCBI chr10:96,640,013...96,653,939
Ensembl chr10:96,639,924...96,653,938
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
gamma-Linolenic Acid inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18324785 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of ASAH1 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr16:53,998,604...54,030,006
Ensembl chr16:53,998,560...54,040,836
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
gamma-Linolenic Acid results in increased activity of CASP3 protein |
CTD |
PMID:16857180 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of CCNA2 protein |
CTD |
PMID:15318936 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of CCNE1 protein |
CTD |
PMID:15318936 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of CDK1 protein |
CTD |
PMID:15318936 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions |
ISO |
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of CLDN5 protein; [gamma-Linolenic Acid co-treated with Iodine] results in increased expression of and results in increased localization of CLDN5 protein; [Selenium co-treated with gamma-Linolenic Acid] results in increased expression of and results in increased localization of CLDN5 protein; gamma-Linolenic Acid results in increased expression of and results in increased localization of CLDN5 protein |
CTD |
PMID:16514648 |
|
NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718
|
|
G |
Clta |
clathrin, light chain A |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of CLTA mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 5:59,490,689...59,509,139
Ensembl chr 5:59,491,096...59,509,138
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of FTH1 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases activity increases expression |
ISO |
gamma-Linolenic Acid results in increased activity of GCLC protein gamma-Linolenic Acid results in increased expression of GCLC mRNA |
CTD |
PMID:17092368 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Grk5 |
G protein-coupled receptor kinase 5 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of GRK5 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 1:282,265,371...282,467,842
Ensembl chr 1:282,265,370...282,462,605
|
|
G |
Hexb |
hexosaminidase subunit beta |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of HEXB mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 2:27,983,925...28,003,260
Ensembl chr 2:27,984,117...28,003,186
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of HMOX1 mRNA; gamma-Linolenic Acid results in increased expression of HMOX1 protein |
CTD |
PMID:17092368 PMID:20664735 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Il2 |
interleukin 2 |
affects expression |
ISO |
gamma-Linolenic Acid affects the expression of IL2 protein |
CTD |
PMID:9415022 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of JUNB protein |
CTD |
PMID:15318936 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Kynu |
kynureninase |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of KYNU mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 3:28,416,926...28,566,939
Ensembl chr 3:28,416,954...28,566,928
|
|
G |
LOC103690190 |
histone H2A type 1-E |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of H2AC6 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr17:44,747,686...44,748,229
Ensembl chr17:44,747,796...44,748,188 Ensembl chr17:44,747,796...44,748,188
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of MAPK3 protein |
CTD |
PMID:15318936 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp11 |
matrix metallopeptidase 11 |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of MMP11 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr20:13,670,051...13,678,834
Ensembl chr20:13,670,066...13,678,089
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of MYC protein |
CTD |
PMID:15318936 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of OCLN protein; [gamma-Linolenic Acid co-treated with Iodine] results in increased expression of and results in increased localization of OCLN protein; [Selenium co-treated with gamma-Linolenic Acid] results in increased expression of and results in increased localization of OCLN protein; gamma-Linolenic Acid results in increased expression of and results in increased localization of OCLN protein |
CTD |
PMID:16514648 |
|
NCBI chr 2:30,527,327...30,577,218
Ensembl chr 2:30,527,715...30,577,218
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
gamma-Linolenic Acid results in increased cleavage of PARP1 protein |
CTD |
PMID:10403056 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of PCNA mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pdlim1 |
PDZ and LIM domain 1 |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of PDLIM1 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 1:259,308,326...259,357,006
Ensembl chr 1:259,308,296...259,357,056
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of PLIN2 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 5:104,984,413...105,010,863
Ensembl chr 5:104,984,414...105,010,857
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
gamma-Linolenic Acid binds to and results in increased activity of PPARA protein |
CTD |
PMID:10403814 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
gamma-Linolenic Acid binds to and results in increased activity of PPARG protein |
CTD |
PMID:15318936 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of PTGR1 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of PTGS2 mRNA |
CTD |
PMID:17092368 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of SKP2 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 2:58,506,146...58,534,211
Ensembl chr 2:58,506,151...58,534,211
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of SLC3A2 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
|
|
G |
St13 |
ST13, Hsp70 interacting protein |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of ST13 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 7:122,585,770...122,635,731
Ensembl chr 7:122,585,771...122,635,731
|
|
G |
Tff3 |
trefoil factor 3 |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of TFF3 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr20:9,850,800...9,855,481
Ensembl chr20:9,850,803...9,855,481
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of TJP1 protein |
CTD |
PMID:16514648 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
gamma-Linolenic Acid results in decreased expression of TNF protein |
CTD |
PMID:9415022 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
gamma-Linolenic Acid inhibits the reaction [Capsaicin results in increased activity of TRPV1 protein] |
CTD |
PMID:17038422 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of TXN mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
gamma-Linolenic Acid results in increased expression of TXNRD1 mRNA |
CTD |
PMID:20664735 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity |
ISO |
linoleamide analog results in increased activity of PPARG protein |
CTD |
PMID:29288688 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions decreases expression increases expression increases phosphorylation increases degradation |
ISO |
1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Phospholipids]]; triacsin C inhibits the reaction [Linoleic Acid results in increased degradation of ABCA1 protein] Linoleic Acid analog results in decreased expression of ABCA1 mRNA Linoleic Acid results in increased expression of ABCA1 mRNA Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA] Linoleic Acid results in increased phosphorylation of ABCA1 protein |
CTD |
PMID:16118212 PMID:18356535 PMID:27939595 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of ABCG1 mRNA; Linoleic Acid results in decreased expression of ABCG1 protein |
CTD |
PMID:16730733 |
|
NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
EXP |
Linoleic Acid results in decreased expression of ACACA mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
increases expression |
EXP |
Linoleic Acid results in increased expression of ACADM mRNA |
CTD |
PMID:23056435 |
|
NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
EXP |
Linoleic Acid results in decreased expression of ACLY mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
decreases expression |
EXP |
Linoleic Acid results in decreased expression of ACMSD mRNA |
CTD |
PMID:18320257 |
|
NCBI chr13:44,424,689...44,468,734
Ensembl chr13:44,424,689...44,468,734
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
increases expression |
EXP |
Linoleic Acid results in increased expression of ACOX1 mRNA |
CTD |
PMID:18320257 |
|
NCBI chr10:104,724,534...104,748,003
Ensembl chr10:104,722,958...104,748,050
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:17374693 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Adipor1 |
adiponectin receptor 1 |
increases expression |
ISO |
Linoleic Acid analog results in increased expression of ADIPOR1 mRNA |
CTD |
PMID:27939595 |
|
NCBI chr13:51,240,470...51,260,233
Ensembl chr13:51,240,911...51,260,228
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
AGER protein results in increased susceptibility to [Azoxymethane co-treated with Glucose co-treated with Linoleic Acid]; Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]] |
CTD |
PMID:22467055 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]] |
CTD |
PMID:18001219 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
increases oxidation |
ISO |
ALOX15 protein results in increased oxidation of Linoleic Acid |
CTD |
PMID:25786526 |
|
NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]] |
CTD |
PMID:16118212 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Ascl2 |
achaete-scute family bHLH transcription factor 2 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of ASCL2 mRNA |
CTD |
PMID:15708366 |
|
NCBI chr 1:216,154,002...216,156,409
Ensembl chr 1:216,154,002...216,156,409
|
|
G |
Bche |
butyrylcholinesterase |
increases expression |
ISO |
Linoleic Acid results in increased expression of BCHE mRNA |
CTD |
PMID:27106529 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of BCL2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of BCL2 protein] |
CTD |
PMID:22467055 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Linoleic Acid results in increased expression of CAT protein |
CTD |
PMID:10946007 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Linoleic Acid results in increased expression of CCL2 protein |
CTD |
PMID:16305726 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
EXP |
[Oleic Acid co-treated with Linoleic Acid] results in increased expression of CD36 mRNA |
CTD |
PMID:28552552 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions affects response to substance |
ISO |
CNR1 protein affects the reaction [Linoleic Acid results in increased secretion of GCG protein] CNR1 protein affects the susceptibility to Linoleic Acid |
CTD |
PMID:30241419 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Linoleic Acid results in increased expression of COL1A1 mRNA |
CTD |
PMID:26240151 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of COL3A1 mRNA |
CTD |
PMID:26240151 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Linoleic Acid results in increased expression of CPT1A mRNA |
CTD |
PMID:11171094 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
Linoleic Acid affects the reaction [PPARA protein binds to CREBBP protein] |
CTD |
PMID:19263263 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
[Oleic Acid co-treated with Linoleic Acid] results in increased expression of CYCS protein |
CTD |
PMID:27016407 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]] |
CTD |
PMID:18001219 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Linoleic Acid results in decreased activity of CYP1A2 protein |
CTD |
PMID:16978661 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions decreases activity |
ISO |
CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP] Linoleic Acid results in decreased activity of CYP2C19 protein |
CTD |
PMID:16978661 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Linoleic Acid results in decreased activity of CYP2E1 protein |
CTD |
PMID:16978661 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
ISO |
Linoleic Acid results in decreased activity of CYP3A4 protein |
CTD |
PMID:16978661 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Linoleic Acid analog results in increased expression of DDIT3 protein |
CTD |
PMID:27939595 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
Linoleic Acid results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:126,894,837...126,911,532
Ensembl chr 5:126,895,286...126,911,520
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
Linoleic Acid results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
Linoleic Acid results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of EDN1 mRNA; Linoleic Acid results in decreased expression of EDN1 protein |
CTD |
PMID:16895544 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of FABP1 mRNA |
CTD |
PMID:15708366 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of FABP3 mRNA |
CTD |
PMID:15708366 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
affects localization |
ISO |
Linoleic Acid analog affects the localization of FABP4 protein |
CTD |
PMID:27939595 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions increases expression |
ISO |
[Linoleic Acid co-treated with Testosterone] results in increased expression of FADS2 mRNA FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein] Linoleic Acid results in increased expression of FADS2 mRNA; Linoleic Acid results in increased expression of FADS2 protein |
CTD |
PMID:21457203 PMID:26240151 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
EXP |
Linoleic Acid results in decreased expression of FASN mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Ffar3 |
free fatty acid receptor 3 |
increases expression |
ISO |
Linoleic Acid analog results in increased expression of FFAR3 mRNA |
CTD |
PMID:27939595 |
|
NCBI chr 1:89,302,035...89,304,064
Ensembl chr 1:89,302,039...89,303,968
|
|
G |
Foxo1 |
forkhead box O1 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of FOXO1 protein |
CTD |
PMID:17374693 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Gcg |
glucagon |
multiple interactions |
ISO |
CNR1 protein affects the reaction [Linoleic Acid results in increased secretion of GCG protein] |
CTD |
PMID:30241419 |
|
NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Linoleic Acid metabolite results in increased expression of GCLM mRNA |
CTD |
PMID:26879219 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
increases abundance |
ISO |
GJB1 protein results in increased abundance of Linoleic Acid |
CTD |
PMID:27859493 |
|
NCBI chr X:71,272,030...71,279,973
Ensembl chr X:71,272,042...71,279,977
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression multiple interactions |
ISO |
Linoleic Acid results in increased expression of GSTA1 mRNA NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA] |
CTD |
PMID:28555106 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA] Linoleic Acid metabolite results in increased expression of HMOX1 mRNA; Linoleic Acid metabolite results in increased expression of HMOX1 protein |
CTD |
PMID:26879219 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
Linoleic Acid analog results in increased expression of HSPA5 protein |
CTD |
PMID:27939595 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Linoleic Acid results in increased expression of IFNG protein |
CTD |
PMID:16305726 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
Linoleic Acid results in increased expression of IL10 protein |
CTD |
PMID:16305726 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Linoleic Acid results in increased expression of IL1B protein |
CTD |
PMID:16305726 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of IL2 protein |
CTD |
PMID:16305726 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of IL4 protein |
CTD |
PMID:16305726 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il5 |
interleukin 5 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of IL5 protein |
CTD |
PMID:16305726 |
|
NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
|
|
G |
Il6 |
interleukin 6 |
affects expression increases expression increases secretion |
ISO |
Linoleic Acid affects the expression of IL6 protein Linoleic Acid results in increased expression of IL6 mRNA Linoleic Acid results in increased secretion of IL6 protein |
CTD |
PMID:16305726 PMID:17374693 PMID:21457203 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Insr |
insulin receptor |
increases expression |
ISO |
Linoleic Acid analog results in increased expression of INSR mRNA |
CTD |
PMID:27939595 |
|
NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases expression |
ISO |
Linoleic Acid analog results in increased expression of LCAT mRNA |
CTD |
PMID:27939595 |
|
NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Linoleic Acid |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Linoleic Acid |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
G |
Lox |
lysyl oxidase |
multiple interactions increases activity |
ISO |
FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein]; TGFB1 protein promotes the reaction [Linoleic Acid results in increased activity of LOX protein] |
CTD |
PMID:26240151 |
|
NCBI chr18:47,500,320...47,577,819
Ensembl chr18:47,500,330...47,577,819
|
|
G |
Lpin1 |
lipin 1 |
decreases expression |
ISO |
Linoleic Acid analog results in decreased expression of LPIN1 mRNA |
CTD |
PMID:27939595 |
|
NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
|
|
G |
Lrat |
lecithin retinol acyltransferase |
increases expression |
EXP |
Linoleic Acid results in increased expression of LRAT mRNA |
CTD |
PMID:12576510 |
|
NCBI chr 2:181,896,304...181,905,366
Ensembl chr 2:181,896,305...181,905,300
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Linoleic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:23288142 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO EXP |
Linoleic Acid results in decreased expression of and results in decreased activity of MMP9 protein [Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of MMP9 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of MMP9 protein] Linoleic Acid results in decreased expression of MMP9 mRNA |
CTD |
PMID:22467055 PMID:23288142 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
Linoleic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein] |
CTD |
PMID:12101222 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
Linoleic Acid affects the reaction [Zymosan analog affects the localization of NCF2 protein] |
CTD |
PMID:12101222 |
|
NCBI chr13:70,226,441...70,259,019
Ensembl chr13:70,226,647...70,257,576
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Linoleic Acid promotes the reaction [PPARA protein binds to NCOA1 protein] |
CTD |
PMID:19263263 |
|
NCBI chr 6:28,677,563...28,931,844
Ensembl chr 6:28,677,540...28,931,843
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Linoleic Acid promotes the reaction [PPARA protein binds to NCOA2 protein] |
CTD |
PMID:19263263 |
|
NCBI chr 5:5,466,544...5,696,540
Ensembl chr 5:5,616,483...5,694,598
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression multiple interactions |
ISO |
Linoleic Acid metabolite results in increased expression of NFE2L2 protein; Linoleic Acid results in increased expression of NFE2L2 mRNA; Linoleic Acid results in increased expression of NFE2L2 protein NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA] |
CTD |
PMID:26879219 PMID:28555106 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of NOS2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of NOS2 protein] |
CTD |
PMID:22467055 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of NOS3 mRNA |
CTD |
PMID:16895544 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Linoleic Acid metabolite results in increased expression of NQO1 mRNA |
CTD |
PMID:26879219 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Linoleic Acid analog |
CTD |
PMID:29515023 |
|
NCBI chr13:53,750,470...53,870,288
Ensembl chr13:53,750,473...53,870,428
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[Glucose deficiency co-treated with Linoleic Acid] results in increased expression of PCK1 mRNA |
CTD |
PMID:8536680 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP |
Linoleic Acid results in increased expression of PDK4 mRNA |
CTD |
PMID:23056435 |
|
NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
|
|
G |
Pld2 |
phospholipase D2 |
multiple interactions |
ISO |
PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]] |
CTD |
PMID:16118212 |
|
NCBI chr10:57,161,921...57,181,148
Ensembl chr10:57,163,174...57,179,730
|
|
G |
Plin1 |
perilipin 1 |
increases expression |
ISO |
Linoleic Acid analog results in increased expression of PLIN1 mRNA |
CTD |
PMID:27939595 |
|
NCBI chr 1:141,458,907...141,470,927
Ensembl chr 1:141,458,181...141,471,010
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions decreases activity |
ISO |
Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] Linoleic Acid results in decreased activity of PON1 protein |
CTD |
PMID:12871208 PMID:15375178 |
|
NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases expression affects abundance increases activity affects binding |
ISO EXP |
[Bezafibrate binds to and results in increased activity of PPARA protein] which results in increased oxidation of Linoleic Acid; Linoleic Acid affects the reaction [PPARA protein binds to CREBBP protein]; Linoleic Acid binds to and results in increased activity of PPARA protein; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA1 protein]; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA2 protein] Linoleic Acid results in increased expression of PPARA mRNA PPARA protein affects the abundance of Linoleic Acid Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of Linoleic Acid]; Linoleic Acid binds to and results in increased activity of PPARA protein Linoleic Acid results in increased expression of PPARA mRNA; Linoleic Acid results in increased expression of PPARA protein Linoleic Acid results in increased activity of PPARA protein Linoleic Acid binds to PPARA protein |
CTD |
PMID:10403814 PMID:11172467 PMID:15491415 PMID:16731579 PMID:18154422 PMID:19263263 PMID:20404010 PMID:23056435 PMID:23619606 PMID:23843199 PMID:25786526 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions decreases expression increases expression increases activity affects binding |
ISO EXP |
Linoleic Acid binds to and results in increased activity of PPARB protein Linoleic Acid results in decreased expression of PPARD mRNA Linoleic Acid results in increased expression of PPARD mRNA Linoleic Acid results in increased activity of PPARD protein Linoleic Acid binds to PPARB protein |
CTD |
PMID:11172467 PMID:15708366 PMID:16731579 PMID:23843199 PMID:25786526 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression increases activity decreases expression |
ISO EXP |
Linoleic Acid binds to PPARG protein Linoleic Acid binds to and results in increased activity of PPARG protein Linoleic Acid results in increased expression of PPARG mRNA resveratrol inhibits the reaction [Linoleic Acid results in increased expression of PPARG protein] Linoleic Acid results in increased activity of PPARG protein Linoleic Acid results in decreased expression of PPARG mRNA; Linoleic Acid results in decreased expression of PPARG protein |
CTD |
PMID:11172467 PMID:12021203 PMID:15708366 PMID:16731579 PMID:18154422 PMID:23843199 PMID:25672876 PMID:25786526 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
EXP ISO |
Linoleic Acid results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
increases expression |
EXP |
Linoleic Acid results in increased expression of PPARGC1B mRNA |
CTD |
PMID:23056435 |
|
NCBI chr18:56,626,725...56,650,524
Ensembl chr18:56,626,712...56,728,968
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP ISO |
Linoleic Acid results in increased expression of PTGS2 mRNA Linoleic Acid inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 mRNA]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:14563831 PMID:18001219 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding multiple interactions |
ISO |
Linoleic Acid binds to RXRA protein Linoleic Acid binds to and results in increased activity of RXRA protein |
CTD |
PMID:16258897 PMID:16731579 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions increases expression |
ISO |
[Linoleic Acid co-treated with Testosterone] results in increased expression of SCD mRNA Linoleic Acid results in increased expression of SCD mRNA; Linoleic Acid results in increased expression of SCD protein |
CTD |
PMID:21457203 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
Linoleic Acid results in increased expression of SERPINE1 mRNA |
CTD |
PMID:17374693 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
decreases activity |
ISO |
Linoleic Acid results in decreased activity of SLC22A6 protein |
CTD |
PMID:29045746 |
|
NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
decreases activity |
ISO |
Linoleic Acid results in decreased activity of SLC22A8 protein |
CTD |
PMID:29045746 |
|
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
|
|
G |
Smad3 |
SMAD family member 3 |
decreases abundance |
ISO |
SMAD3 protein results in decreased abundance of Linoleic Acid |
CTD |
PMID:23034213 |
|
NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
Linoleic Acid results in decreased expression of SREBF1 mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
TGFB1 protein promotes the reaction [Linoleic Acid results in increased activity of LOX protein] |
CTD |
PMID:26240151 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
decreases response to substance |
ISO |
Linoleic Acid results in decreased susceptibility to TNF protein |
CTD |
PMID:22683933 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
ISO |
TRPV1 results in increased susceptibility to [Linoleic Acid co-treated with Freund's Adjuvant] |
CTD |
PMID:23006841 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Ucp2 |
uncoupling protein 2 |
increases expression |
EXP |
Linoleic Acid results in increased expression of UCP2 mRNA |
CTD |
PMID:11341955 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of VEGFA protein] |
CTD |
PMID:22467055 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Wnt10b |
Wnt family member 10B |
decreases expression |
ISO |
Linoleic Acid results in decreased expression of WNT10B mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 7:140,448,284...140,466,159
Ensembl chr 7:140,448,465...140,454,268
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases lipidation |
ISO |
Ascorbic Acid promotes the reaction [linoleic acid hydroperoxide results in increased lipidation of AGT protein modified form] |
CTD |
PMID:26111765 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Cygb |
cytoglobin |
increases metabolic processing |
EXP |
CYGB protein results in increased metabolism of linoleic acid hydroperoxide |
CTD |
PMID:11320098 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases reduction |
ISO |
GPX1 protein results in increased reduction of linoleic acid hydroperoxide |
CTD |
PMID:8428933 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases reduction |
ISO |
GPX2 protein results in increased reduction of linoleic acid hydroperoxide |
CTD |
PMID:8428933 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form] |
CTD |
PMID:29969931 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA] |
CTD |
PMID:16415877 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions affects abundance |
EXP |
zileuton inhibits the reaction [ALOX5 protein affects the abundance of lipoxin A4] |
CTD |
PMID:15326064 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:23063943 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] |
CTD |
PMID:23063943 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein] |
CTD |
PMID:10377187 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Fpr2 |
formyl peptide receptor 2 |
multiple interactions increases activity |
ISO EXP |
[Aspirin results in increased abundance of lipoxin A4] which results in increased expression of FPR2; lipoxin A4 analog binds to and results in decreased activity of FPR2 protein lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FPR2 mRNA] lipoxin A4 results in increased activity of FPR2 |
CTD |
PMID:12594298 PMID:19597002 PMID:21765620 |
|
NCBI chr 1:59,800,558...59,809,507
Ensembl chr 1:59,800,984...59,802,401
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP |
lipoxin A4 results in increased expression of HMOX1 mRNA; lipoxin A4 results in increased expression of HMOX1 protein lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer] |
CTD |
PMID:23826208 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
affects response to substance |
ISO |
ICAM1 protein affects the susceptibility to lipoxin A4 |
CTD |
PMID:7602232 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein] |
CTD |
PMID:29969931 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions decreases secretion |
ISO |
lipoxin A4 analog results in decreased expression of IL1B protein 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] lipoxin A4 analog results in decreased secretion of IL1B protein lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein] |
CTD |
PMID:10377187 PMID:21659618 PMID:21831303 PMID:29969931 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
increases secretion |
ISO |
lipoxin A4 analog results in increased secretion of IL4 protein |
CTD |
PMID:10377187 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased secretion of IL6 protein] |
CTD |
PMID:27663891 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21831303 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21831303 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
ISO |
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; [lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein] |
CTD |
PMID:29969931 |
|
NCBI chr 1:48,076,761...48,108,218
Ensembl chr 1:48,077,033...48,108,216
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein] |
CTD |
PMID:29969931 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization multiple interactions |
EXP |
lipoxin A4 affects the localization of NFE2L2 protein lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer] |
CTD |
PMID:23826208 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein] |
CTD |
PMID:21831303 PMID:29969931 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:21831303 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein] |
CTD |
PMID:12223454 PMID:20709806 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions decreases phosphorylation |
ISO |
lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein] |
CTD |
PMID:12223454 PMID:20709806 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
lipoxin A4 binds to and results in increased activity of PPARG protein |
CTD |
PMID:19321784 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions |
ISO |
[WEB 2086 binds to and results in decreased activity of PTAFR protein] which results in decreased susceptibility to lipoxin A4 |
CTD |
PMID:7602232 |
|
NCBI chr 5:150,746,284...150,775,675
Ensembl chr 5:150,754,021...150,775,672
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions affects abundance |
EXP |
[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PTGS2 protein; Celecoxib inhibits the reaction [PTGS2 protein affects the abundance of lipoxin A4]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein] |
CTD |
PMID:15326064 PMID:21765620 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] |
CTD |
PMID:21831303 PMID:23063943 PMID:29969931 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Selp |
selectin P |
affects response to substance |
ISO |
SELP protein affects the susceptibility to lipoxin A4 |
CTD |
PMID:7602232 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions increases expression |
ISO |
AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA] lipoxin A4 results in increased expression of SOCS2 mRNA; lipoxin A4 results in increased expression of SOCS2 protein |
CTD |
PMID:16415877 |
|
NCBI chr 7:36,495,496...36,500,878
Ensembl chr 7:36,495,480...36,499,784
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein] 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:10377187 PMID:21575454 PMID:21831303 PMID:23063943 PMID:29969931 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
affects expression |
EXP |
Soybean Oil affects the expression of ABCB11 mRNA |
CTD |
PMID:15770074 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects expression |
EXP |
Soybean Oil affects the expression of ABCB1B mRNA |
CTD |
PMID:15770074 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
affects expression |
EXP |
Soybean Oil affects the expression of ABCB4 mRNA |
CTD |
PMID:15770074 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects expression |
EXP |
Soybean Oil affects the expression of ABCC1 mRNA |
CTD |
PMID:15770074 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects expression |
EXP |
Soybean Oil affects the expression of ABCC2 mRNA |
CTD |
PMID:15770074 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
affects expression |
EXP |
Soybean Oil affects the e | |